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Plasma levels and dialysance of atrial natriuretic peptide in terminal
renal failure. Plasma immunoreactive atrial natriuretic peptide (irANP)
levels, their chromatographic profile, relationship with hemodynamic
variables, and responses to hemodialysis (HD) or postural changes
were investigated in HD patients. Peripheral venous supine plasma
irANP averaged 167 31 (±sEM) pg/mI in 12 normal subjects (age 63
2 yr). In 42 HD patients (mean age 65 I yr), plasma irANP in
peripheral arterio-venous fistulae was high (447 50 pg/mI, P < 0.01)
before HD and decreased (P < 0.001) to 164 24 pg/ml after HD. The
latter reduced body weight by —2.3 0.2 kg (P < 0.001) and blood
pressure from 139/77 4/2 to 126/73 4/2 mm Hg (P < 0.01).
Pre-dialysis plasma irANP in right atrium, pulmonary artery or av-
fistula correlated with pulmonary capillary wedge pressure (N = 10, r =
0.66 to 0.73; P < 0.05); HD-induced changes in these variables were
also correlated (r = 0.80 to 0.90; P < 0.05 to < 0.01). Compared with
supine values, upright posture decreased plasma irANP in 12 normal
subjects and 8 HD patients (—40 and —42%, respectively, P < 0.01).
IrANP clearance from plasma averaged 24 5 mI/mm across the
hemodialyzer (N = 6) and 46 3 mI/mm across the hetnofilter (N = 4).
We conclude that in terminal renal failure, circulating irANP consists
largely of aANP, is often elevated before HD, decreases with the
change from recumbency to standing, falls after removal of excess fluid,
and may depend strongly on left atrial and pulmonary arterial pressures.
Elimination of irANP across dialyzers or ultrafilters contributes only
little to reduction in plasma irANP during HD. In addition to the cardiac
state, age and posture should be considered when interpreting plasma
1rANP levels as a possible index of fluid overload.
The atrial natriuretic peptide (ANP) system may play an
important role in the regulation of blood pressure (BP), the
body sodium—fluid volume state, and kidney function [1, 2]. In
normal man, a prohormone with 126 amino acids is stored in the
atrial myocytes, while ahANP, which contains 28 amino acid
residues, is released into the circulation. ANP secretion seems
to increase mainly in response to atrial distension [3, 4]. A rise
in plasma immunoreactive ANP (irANP) levels has been dem-
onstrated in healthy humans following intravenous saline load-
ing [5, 6], a central shift of circulating volume produced by the
change from standing to recumbency [7, 8] or water immersion
[9, 10], a vasoconstrictor hormone—induced acute elevation in
BP and hence afterload [11], and acutely increased sodium
intake [6, 12]. On the other hand, synthetic ahANP given as a
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steady—state infusion produced, in addition to diuresis and
natriuresis, a BP reduction, plasma volume contraction, and a
spectrum of other renal, endocrine and metabolic effects [6,
13—151.
If the ANP system is sensitive to sodium—fluid retention,
circulating irANP should be elevated in states with impaired
renal excretory capacity. In fact, raised plasma irANP concen-
trations were observed in children with end—stage kidney
disease [16]. In the latter, ultrafiltration reduced both the
volume overload and plasma irANP levels, but a possible
removal of irANP across the dialyzer was not evaluated. High
plasma Ii-ANP values were also reported in some adult hemo-
dialysis (HD) patients ([6, 17]; however, interpretation is lim-
ited because the patients may have been older than the normal
subjects used for comparison. Age is an important factor in the
regulation of ANP. Circulating irANP increases in normal
humans from the third to the seventh decade of life [8, 18]. The
present study was undertaken to assess basal (pre-dialysis)
levels of circulating irANP and the response to removal of
excess sodium—fluid by ultrafiltration in a population of adult
HD patients. To further clarify regulatory aspects in dialysis—
treated terminal renal failure, the chromatographic characteris-
tics of circulating ANP, the relationships between hemody-
namic variables and regional plasma irANP concentrations, the
effects of posture on plasma irANP, and IrANP losses across
the dialyzer were also investigated.
Methods
Effects of hemodialysis on peripheral plasma irANP and
some possible correlates (Study A)
Forty-two patients (16 men and 26 women, mean age 65 1
years, (±sEM) with terminal renal failure, who had been hemo-
dialyzed for an average of 4.9 0.6 yr, were studied. Clinical
features are summarized in Table 1. The renal diagnosis,
established by clinical and laboratory criteria andlor renal
biopsy was interstitial nephritis in 25 (20 with probable analge-
sic nephropathy), polycystic kidney disease in five, glomerulo-
nephritis in four, urogenital tuberculosis in two, reflux nephrop-
athy, diabetic nephropathy and nephrosclerosis each in one
patient; no etiological classification could be made in three
cases. Additional diagnoses included coronary heart disease in
12, chronic obstructive pulmonary disease in four, and periph-
eral occlusive arterial disease in three patients; nine patients
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were without evidence of extra—renal disease. On the day of
study, pre-dialysis supine BP was normal (140/90 mm Hg) in
18, in the borderline range (141/91 to 159/94 mm Hg) in 15,
elevated to 160/95 mm Hg in five, and in the hypotensive
range (systolic BP <90 mm Hg) in four patients. Patients with
congestive heart failure, retinal hemorrhages or papilledema,
aortic aneurysm or advanced liver disease were excluded from
study. Any antihypertensive drug which had previously been
given was discontinued at least 14 days before study. Medica-
tions which were continued included low dosed, platelet aggre-
gation inhibitors in 24 patients, benzodiazepines in 16, tricyclic
antidepressants in six, cyclooxygenase inhibitors in five, digi-
talis or nitrates each in four, and insulin in one patient. The
patients were instructed to follow their usual diet (sodium 40 to
65 mEq/day, potassium 40 to 50 mEq/day) and fluid intakes.
The patients underwent regular HD or hemofiltration (N = 2)
for 3.8 0.5 hours two or three times weekly. For HD,
commercial dialyzers (Beilco Unimt, Beilco, Mirandola, Italy;
and Miro I, Dialysetechnik Ettlingen, FRG) with cuprophane
membranes (Prima M or H, Bellco) were utilized. Heparin was
used as an anticoagulant in all patients with an initial loading
dose of 2500 IU and continuous or intermittent infusion of 500
to 1000 lU/hour. The initial dialysate composition was: sodium
138, potassium 1.5 or 3.0, calcium 3.5, magnesium 1.0, chloride
108 or 109.5, and acetate 36 mEq/liter. In eight patients,
bicarbonate was used instead of acetate. Blood flow to the
dialyzer was increased from 100 to 200 mI/mm within the first 30
minutes and, thereafter, kept constant.
Hemofiltration was performed using a Hamoprocessor
Sartorius 400 05 (Sartorius Membranfilter GmbH, Göttingen,
FRG) with a Gambro Fiberhämofilter FH77 (Gambro, Lunde,
Sweden). Ultrafiltrate was replaced 1: 1 minus the expected
volume overload, by 20 to 25 liters of electrolyte solution
containing sodium 135, potassium 0 or 2, calcium 3.8, magne-
sium 1.5, chloride 106.5 or 108.5, and lactate 33.7 mEq/liter.
Blood flow was increased from an initial 130 mI/mm to a
maximum steady rate of 350 ml/min.
All patients gave their informed consent prior to the study.
They remained supine from 30 minutes before until the end of
dialysis. During the first 15 minutes of HD or hemofiltration, BP
and heart rate were measured in triplicate. Thereafter, blood
samples were taken from the arteriovenous (av) fistula into
pre-cooled tubes for analysis of hematocrit, plasma sodium,
potassium, chloride, calcium, phosphate, protein, albumin,
urea, creatinine, and irANP. During the last 15 minutes of HD
or hemofiltration, these measurements were repeated.
Regional plasma irANP as related to hemodynamics before
and after hemodialysis (Study B)
Ten chronic HD patients (4 women, 6 men, mean age 46 6
yr) were studied. Total duration of regular HD averaged 48 16
months; dialysis was performed four hours three times a week.
The renal diagnosis established by clinical and laboratory
criteria and/or renal biopsy was glomerulonephritis in five,
interstitial nephropathy in four and nephroangiosclerosis in one
patient. The residual renal function, evaluated by 24 hour
creatinine clearance, averaged 3 2.6 mllmin/l .73 m2. Five had
left ventricular hypertrophy as shown by electrocardiography
and chest X-ray. On the day of study, pre-dialysis supine BP
was normal in two, in the borderline range in two, and elevated
to >160/95 mm Hg in six patients. Exclusion criteria, dietary
instructions and withdrawal from previous antihypertensive
drugs were similar as in study A.
All subjects gave their informed consent prior to the study,
which was performed in the morning in conjunction with a
regularly scheduled HD. Pre-dialysis body weight, supine and
upright BP, and heart rate were measured. A Swan—Ganz
catheter (7F-Edwards Laboratories, Santa Ana, California,
USA) was placed via a subclavian vein in the right heart and the
pulmonary artery. The catheter was left in place during the
entire procedure. After 30 to 45 minutes of equilibration in the
supine position, the hemodynamic measurements were per-
formed and blood samples were collected simultaneously from
right atrium, pulmonary artery, the av-fistula and the femoral
vein for determination of irANP, hematocrit, total protein,
plasma creatinine, sodium and potassium. Immediately there-
after, HD was initiated and continued for four hours, utilizing a
1 to 1.3 m2 cuprophane membrane hemodialyzer (Gambro
Lundia, Hechingen, FRG), a dialysate containing sodium 140,
potassium 2, calcium 3.5 and acetate 35 mEq/liter. Ultrafiltra-
tion was performed in each patient in an attempt to reach the
estimated "dry—weight"; this was monitored with a bed—scale.
Thirty to 45 minutes after the end of HD, hemodynamic
measurements and regional blood sampling for post-dialysis
values were again taken. Thereafter, the catheter was removed
and the final determinations of body weight, heart rate and BP
were obtained.
Removal of plasma irANP across dialyzer or hemofilter
(Study C)
Removal of circulating irANP across the dialyzer or the
hemofilter (Prima M, Belico; or Gambro FH77, Gambro) was
assessed in six and four patients, respectively. irANP was
determined at the inlet and outlet of the dialyzer or hemofilter,
Table 1. Clinical features of the 42 terminal renal failure patients
included in study A (mean sEal)
Age yr
Sex (male/female)
Weight before treatment kg
"Dry" body weight kg
Height cm
Ongoing hemodialysis years
Duration of one hemodialysis hr
Hemodialysis frequency per week
Systolic blood pressure mm Hg
Diastolic blood pressure mm Hg
Heart rate bpm
Plasma sodium mEq/Iiter
potassium mEq/liter
chloride mEq/iiter
calcium mmol/liter
phosphate mmoi/iiter
urea mg/dl
creatinine mg/dl
protein giliter
albumin giliter
Hematocrit %
Remnant diuresis mi/day
65 1.3
16/26
64.9 2.1
62.3 2.1
163 1.5
4.8 0.6
3.8 0.1
2.7 0,1
139 4
77 2
78 2
139 1
5.6 0.1
100 1
2.5 0.0
1.5 0.1
83 4
10.7 0.3
70 1
31 1
27 I
226 55
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For determination of plasma irANP, 10 ml of blood were
collected in pre-cooled glass tubes containing K-EDTA (1.5 mg
per ml of blood), aprotinin (1000 kallikrein—inactivating U/mi)
and soybean trypsin inhibitor (z-n-benzoyl-l-arginine ethyl es-
ter, 100 U/mi). For studies B, C and D, the samples of blood,
dialysate or ultrafiltrate were taken into polypropylene tubes
containing 1 mg/mi Na-EDTA. The samples were mixed, im-
mediately centrifuged at 4°C, and plasma was stored at —20°C
until assay. The dialysate or ultrafiltrate samples were extracted
immediately after collection. Plasma (2 ml), dialysate (1 liter)
and ultraflitrate (5 ml) were extracted by passing the samples
through C18 octadecyl silica cartridges (Sep-Pak C18, Waters,
Milford, Massachusetts, USA) and eluted with 0.1% trifluor-
acetic acid in 100% ethanol. The efficiency of the extraction
procedure was estimated by recovery of radiolabeled or syn-
thetic ahANP. Recovery of synthetic ahANP from 2 ml of
plasma over the range 4 to 500 pg/mi averaged 91 4% (N = 8)
after extraction and radioimmunoassay procedures. Extraction
of radioiabeled (20,000 cpm) ahANP from 5 ml of hemoflitrate
or 1 liter of dialysate averaged 96 1% (N = 3), and 59 5%
(N = 5), respectively. The lower recovery from dialysate is due
to the fact that Sep-Pak extraction of ahANP is dependent upon
extraction volume; recovery decreased progressively from 82
4 to 70 11 and 65 11% as the volume of extraction increased
from 50 to 500 and 1000 ml of dialysate, respectively. Radioim-
munoassay of irANP was performed [19] using a rabbit anti-
ANP antibody (Peninsula Laboratories Europe Ltd, Mersey-
side, UK). This antibody shows complete cross reactivity with
ahANP and rat atriopeptin III, but has no cross reactivity with
somatostatin, oxytocin or vasopressin. The standard buffer was
0.1 M Tris, pH 7.4, containing 0.1% bovine serum albumin (RIA
grade), 0.1% Triton X-100, 0.2 g/iiter neomycine suiphate, and
0.1 g/liter sodium azide. 1251-ahANP was used as tracer
(Amersham Buchler, Braunschweig, FRG; specific activity,
2000 Cilmmoi), and synthetic ahANP (Bissendorf Peptide
GmbH, Wedemark, FRG) was used to construct standard
curves. Incubation was carried out for 48 hours at 4°C. Bound
and free '251-ahANP were separated by adding dextran—coated
charcoal; the lowest concentration of irANP detected was 4
pg/tube, and the 50% intercept 30 pg/tube. The interassay
variation was 15.5% (N = 6), and the intraassay variation 7.8%
(N = 6). All plasma values were calculated from standard curve
extracted from 2 ml of plasma over the range 4 to 1000 pg/mi
_______________________
aftercorrection for non-specific binding of tracer. Dialysate and
hemoflitrate concentrations of irANP were calculated by com-
parison with non-extracted standard curves and corrected for
recovery.
In normal subjects, circulating irANP was previousiy char-
acterized by reverse—phase HPLC and found to correspond
largely to ahANP [14]. Characterization of plasma irANP in
dialysis patients was performed by reverse—phase HPLC using
a Waters 2 pump system and a Radial Pak C'8 column (5 X 100
mm). Plasma (2 ml) was extracted on a Sep-Pak C'8 cartridge as
described above, ciuted with 0.1% trifluoroacetic acid in etha-
nol and evaporated to dryness under nitrogen. The residue was
dissolved in 0.1 M HCI and applied to the HPLC column.
Chromatography was performed with 0.1% trifluoroacetic acid
and linear gradient elution system form 20 to 80% ethanol over
40 minutes. Fractions (1 ml) were collected, dried under nitro-
gen and assayed for ANP-like material by RIA.
as well as in the dialysate or uitrafiltrate, respectively. These
measurements were performed at the beginning (within the first
10 mm) and end (within the last 10 mm) of the four hour HD or
hemofiltration treatment.
Postural influence on circulating irANP (Study D)
In eight of these patients, the influence of posture on plasma
irANP levels was evaluated on a non-diaiysis day (15 to 44
hours after the last HD). Blood samples from a peripheral vein
and measurements of BP and heart rate were obtained after one
hour of recumbency and subsequently after one hour of stand-
ing.
Normal subjects
Twelve normal subjects matched for age (mean 63 2 yr),
with the patients in study A evaiuated to define normal plasma
1rANP values for this age group during standing and recum-
bency. Ali were healthy volunteers with a BP <140/90 mm Hg
and none was taking any medication. After giving their in-
formed consent to the study, they were instructed to continue
with their usual diet. During the 24 hours preceding the study,
urinary sodium excretion averaged 210 23 mEq, potassium
excretion 72 8 mEq and creatinine clearance 97 6 mllmin/
1.73 m2. Blood samples for determination of irANP and mea-
surements of BP and heart rate were obtained after one hour of
recumbency and subsequently after one hour of standing.
Analytical methods
BP was determined by using sphygmomanometry (Korotkoff
sound V for diastolic BP); for the hemodynamic studies an
automatic recorder (Dynamap, Applied Medical Research Com-
pany, Tampa, Florida, USA) was used. The heart rate was
derived from ECG. The right atrial pressure (RAP), puimonary
arterial pressure (PAP), and pulmonary capillary wedge pres-
sure (PCWP) were measured with a P23 Id physiological signals
Transducer (Statham Gould, Hato Rey, Puerto Rico) and mon-
itored with a muitichannel recorder (Heilige, Freiburg, FRG).
The cardiac output was determined by thermodilution (COM
1-Edwards Laboratories, Santa Ana, California, USA); the
mean value of six determinations was used to calculate the
following hemodynamic paramters:
cardiac output (liter/mm)Cardiac index = 2body surface (m)
Total peripheral vascular resistance =
[mean arterial pressure — mean RAP (mm Hg)] x 80
cardiac output (liter/mm)
Pulmonary vascular resistance =
[mean PAP — mean PCWP (mm Hg)] x 80
cardiac output (iiter/min)
Hematocrit was measured in triplicate by the microcrit meth-
od, plasma sodium and potassium by flame photometer, chlo-
ride, calcium, phosphate, albumin, and creatinine by Greiner
autoanalyzer (Greiner SA, Langenthal, Switzerland), and
plasma protein by the Biuret method.
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Effects of hemodialysis (Study A)
Fig. 1. Reverse—phase high performance liquid chromatography pro-
file of circulating irANP from dialysis patients (I), and 500 pg of
synthetic ahANP (0).
Statistical analysis was performed using SAS software pack-
age (Statistical Analysis System, Version 5.0 Cary, North
Carolina, USA). Methods included independent t-test for com-
parison of basal values between groups, paired t-test for 2 point
measurements within the patients, and linear regression analy-
sis. For better normal distribution, natural logarithmic transfor-
mation was applied to 1rANP concentrations. Values are given
as mean SEM.
Results
Characterization of irANP in plasma of hemodialysis patients
The material in plasma extracts from HD patients measured
by the RIA was either identical with or very closely related to
ahANP. Serial dilution of extracts inhibited binding of 125j
ahANP to the antiserum in parallel with synthetic ahANP.
Furthermore, when plasma extracts were subjected to HPLC,
the major peak of immunoreactive material eluted at the posi-
tion corresponding to synthetic ahANP (Fig. 1).
Before HD, mean body weight exceeded the estimated "dry"
weight by 2.6 1.0 kg (Table 1). HD reduced weight by 2.3
1.0 kg (P < 0.001) and BP from 139 4/77 2 to 126 4/73
2 mm Hg (P < 0.01), while heart rate increased from 78 2 to
84 2 bpm (P < 0.001). Compared with BP in the normal
subjects (126 5/79 2 mm Hg), HD patients had a higher
systolic BP before (P < 0.01) but not after HD. Compared with
pre-dialysis values, hematocrit increased during HD by 6.4%,
total plasma protein by 8.1%, and albumin by 9.7% (P <0.001).
Plasma potassium, chloride and phosphate were reduced by 1.8
0.4, 1.7 1.5 and 0.56 0.19 mEq/liter, respectively (P <
0.001); while sodium was constant and calcium increased by
0.35 0.11 mEq/liter (P < 0.001). Plasma creatinine decreased
from 10.7 0.3 to 5.2 0.2 mg/dl and urea levels from 83.3
3.6 to 33.0 1.8 mg/dl, respectively (P < 0.001).
Supine plasma irANP concentration in av-fistulae averaged
447 50 pg/mI before HD and decreased to 164 24 pg/mI after
HD (P < 0.001) (Fig. 2). Compared with peripheral venous
irANP in normal subjects (167 31 pg/mi), levels in the patients
were elevated significantly before (P < 0.01) but not after
dialysis. Absolute plasma irANP values correlated with systolic
BP or age following HD (r = 0.35 and 0.31, respectively; P <
0.05); these correlations just missed statistical significance
before HD (r = 0.29 and 0.30, respectively). On the other hand,
RD-induced changes in plasma irANP correlated inversely with
those in hematocrit (r =
—0.41, P < 0.01).
To evaluate a possible association between plasma irANP
and variations in BP, a subgroup of patients with a normal
pre-dialysis BP was compared with hypertensive patients (BP>
160/95 mm Hg before dialysis). Pre-dialysis levels of plasma
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Fig. 3. Comparative effects of hemodialysis on plasma immunoreac-
live atrial natriuretic peptide (irANP), mean blood pressure and hem-
atocril in normotensive and hypertensive hemodialysis patients. Values
are given as mean SEM.
irANP averaged 411 51 pg/mi in normotensive and 782 194
pg/mi in hypertensive patients. HD produced a similar increase
in hematocrit in the two subgroups (Fig. 3); nevertheless, mean
BP was reduced significantly more in hypertensive than in
normotensive patients (P < 0.001); the concomitant decrease in
plasma irANP showed the same pattern, although the difference
did not achieve statistical significance.
Regional plasma irANP as related to hemodynamics before
and after hemodialysis (Study B)
Before HD, body weight exceeded the estimated "dry"
weight on average by 2.8 kg, while BP, cardiac index (normal
range 2.8 to 4.2 liter/minIm2), RAP (normal value 6 mm Hg),
mean PAP (normal range 10 to 16 mm Hg), PCWP (normal
upper limit 12 mm Hg), and pulmonary vascular resistance
(normal range 60 to 120 dyn. sec cm5) tended to be high.
Pre-dialysis irANP levels in peripheral av-fistula or venous
blood averaged 411 93 and 338 85 pg/mi, respectively.
IrANP concentrations in right atrium were only insignificantly
higher than the values in the pulmonary artery, but exceeded
peripheral venous irANP levels on average 35% (P < 0.001).
HD lowered body weight on average by 2.7 kg. This was
accompanied by significant (P < 0.05 to < 0.001) increases in
hematocrit and plasma protein and decreases in BP, total
peripheral vascular resistance, RAP, PAP, PCWP, and plasma
irANP in all regions evaluated (Table 2). Plasma sodium in-
creased slightly from 137 ito 139 1 mEq/liter, while plasma
potassium and creatinine decreased from 5.1 0.2 to 3.6 0.1
mEq/liter and 13.2 0.7 to 6.1 0.5 mg/dl, respectively (P <
0.001).
Table 2. Regional plasma irANP levels and hemodynamics in 10
patients before and after hemodialysis (mean sEM)
Hemodialysis
Before Alter
Body weight" kg 72.8 6.3 70.1 59a
Blood pressure
mm Hg 162/89 7/4 138/78 7/4"
Total peripheral vas-
cular resistence
dyn . sec cm5 1158 97 1013 82b
Cardiac mdcx
liter/minIm2 4.25 0.31 4.40 0.27
Heart rate bpm 80 3 88 5"
Hematocrit % 23.9 1.4 26.9 1.7c
Plasma protein glliter 70.3 1.02 75.5 2.2k'
Right atrial pressure
mmHg 8±3 0.8±0.5"
Pulmonary arterial
pressure mm Hg 28 5 16 2d
Pulmonary capillary
wedge pressure
mmHg 15±3 61d
Pulmonary vascular
resistance
dyn . sec• cm5 149 42 102 20b
Plasma irANP pg/mi
right atrium 523 108 160 22" (N = 9)
pulmonary artery 446 90 143 l9C
peripheral arterio-
venous fistula 411 93 100 27" (N = 8)
femoral 338 85 119 30" (N = 9)
" estimated dry body weight, 70 5 kgb P< 0.05
P < 0.01
d p < 0.001 vs. before dialysis
Pre-dialysis irANP levels in right atrial, pulmonary arterial or
av-fistula plasma correlated positively with PCWP (r = + 0.66
to + 0.73; P < 0.05); while a tendency for similar relationship
between peripheral venous plasma irANP and PCWP (r = 0.56),
or betwen plasma irANP in all four regions and PAP (r = +0.44
to +0.61) did not reach statistical significance. Pre-dialysis
regional irANP values in this group did not correlate with RAP.
HD-induced absolute or percentage changes in right atrial,
pulmonary arterial or av-fistula plasma irANP correlated with
those in PCWP (r +0.80 to +0.90, P < 0.05 to <0.01);
changes in pulmonary arterial plasma iTANP correlated also
with those in PAP (r = + 0.80). A tendency for similar relation-
ship between dialysis—induced changes in peripheral, venous
plasma irANP and PCWP or PAP (r = +0.59 to +0.70) did not
reach statistical significance. Dialysis—induced changes in re-
gional irANP values did not correlate significantly with those in
RAP. Finally, variation in pulmonary arterial and peripheral
av-fistula or venous plasma irANP correlated with the
ultrafiltration—induced decreases in body weight (r = +0.78 to r =
+0.82, P < 0.05).
Removal of plasma irANP across dialyzer or hemofilter
(Study C)
Passage through a hemodialyzer reduced plasma irANP from
530 146 at the inlet to 397 119 pg/ml (—25%, P < 0.01) at
the outlet of the dialyzer during the first 10 minutes of dialysis
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Fig. 4. Rates of circulating immunoreactive atrial natriuretic peptide
removed across hemodialyzer (A) or hemofilter (B) and appearing in
dialysate or ultrafiltrate, respectively. Values are given as means
SEM. Symbols are: () start, (D) end.
andfrom429 115to373 ll4pg/ml(—13%,P<0.0l)during
the last 10 minutes. Using hemofiltration, these values de-
creased from 625 128 to 324 63 pg/mI (—48%, P < 0.05) and
from 321 94 to 242 76 pg/mi (—25%, P < 0.05), respec-
tively. IrANP removal rates from plasma averaged 25 5
mi/mm for the dialyzer and 46 3 mI/mm for the hemofilter
(Fig. 4). Ten to 19% (dialyzer) or 15 to 67% (hemofilter) of
irANP removed from plasma was detected in HD fluid.
Postural influence on circulating ANP (Study D)
Compared to supine values, av-fistula plasma irANP de-
creased after one hour of standing from 1008 178 to 583 94
pg/ml (—42%, P < 0.01) in the HD patients and peripheral
venous irANP from 167 31 to 101 21 pg/mI (—40%, P <
0.01) in the normal subjects (Fig. 5).
Discussion
The findings of the present study demonstrate that in patients
with terminal renal failure, circulating irANP consists largely of
ahANP, is often high before HD, falls with the change from
recumbency to standing, decreases towards normal values after
removal of excess fluid by dialysis, and correlates with PCWP
and/or PAP.
Normal
subjects
N = 12
Fig. 5. Supine (E) and upright (D) levels of immunoreactive, atrial
natriuretic peptide in plasma of hemodialysis patients or normal
subjects. Values are given as mean SEM. (*) P < 0.01 versus supine
position.
Previous reports of high plasma irANP in adults [6, 17] or
children [16] maintained on HD did not evaluate possible
influences of age and/or posture. Considering the markedly
higher circulating irANP levels in elderly as compared with
young normal subjects [8, 18], consideration of this factor in
patients with renal or other disorders is important. This is
emphasized by the finding that supine plasma irANP levels
observed after removal of excess fluid in our HD patients
correlated with age (r = +0.31, P < 0.05), and on average were
no longer significantly different from healthy humans of similar
age (study A). On the other hand, the lack of this relationship
before dialysis suggests that, in the interval between consecu-
tive HD treatments, other factors influencing the ANP-system
gain increasing regulatory importance. Furthermore, since
irANP was on average 22% higher in plasma from av-fistula
than from peripheral veins (Study B), the difference between
HD patients (av-plasma) and normal subjects (venous plasma)
in study A may be correspondingly overestimated. However,
when corrected for this, pre-dialysis irANP concentrations
were still significantly higher in HD patients than in normal
subjects (P < 0.01).
Atrial distension [3, 4] secondary to overhydration [6, 8]
and/or increased systemic BP and, thus, afterload [11] may be
the major cause of elevated plasma irANP levels in end—stage
kidney disease. Several arguments support this contention. In
humans with heart disease but without renal failure, circulating
IrANP concentrations have been found to correlate positively
with RAP and/or PCWP [20, 21]. Moreover, in our HD patients
so studied, pre-dialysis irANP levels in right atrial, pulmonary
arterial or av-fistula plasma correlated positively (P < 0.05)
with PCWP, and HD-induced changes in right atrial, pulmonary
arterial or peripheral arterial plasma correlated with those in
PCWP and/or PAP. In HD patients, these pressures correlate in
turn closely with the state of hydration [22]. The role of the
latter in regulating plasma ANP in our HD patients is supported
by positive correlations between ultrafiltration—induced de-
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creases in body weight and associated changes in pulmomary
arterial, av-fistula and venous plasma irANP in study B (r =
+0.78 to +0.82, P < 0.05), and by the inverse relationship
between HD-induced changes in plasma irANP levels and those
in hematocrit in study A (r =
—0.41, P < 0.01). Additionally,
the removal of 2.3 liters of excess fluid in the HD patients in
study A was accompanied by a 62% reduction in plasma irANP,
whereas an acute load of 2.14 liters of 0.9% saline in healthy
humans of similar age produced a 49% elevation in circulating
irANP [8]. Furthermore, isovolemic HD reportedly failed to
modify irANP levels [23]. In addition to the findings which
implicate central hypervolemia as an important determinant of
circulating irANP, a contribution of systemic BP per se should
also be considered. The tendency for systolic BP to correlate
with absolute irANP levels in our patients reached statistical
significance after HD. Moreover, a subgroup—analysis of nor-
motensive versus hypertensive patients indicated that a greater
HD-induced BP-reduction in the hypertensive subgroup was
accompanied by a parallel tendency for a more pronounced
decrease in irANP, despite a similar increase in hematocrit and,
thus, plasma volume contraction within the two subgroups.
Nevertheless, this tendency might also simply reflect greater
pre-dialysis volume expansion and greater effectiveness of the
"same" relative volume reduction on both BP and irANP.
Whether the half—life (in normal subjects on average 3.2 mm)
[24] and the total clearance of plasma ANP (2.4 liter/mm) [25]
are altered in terminal renal failure is presently unknown.
During its passage through human kidneys, about 50% of
endogenous irANP disappears from the plasma [6]. Assuming a
total renal plasma flow of 600 mllmin/l .73 m2, no more than 12%
of the overall irANP plasma clearance in normal man can be
attributable to kidney—based mechanisms. Even a total loss of
renal excretory and metabolic capacity would, therefore, con-
tribute minimally to the markedly increased plasma irANP
concentrations in end—stage kidney disease.
During dialysis, a fraction of circulating irANP was cleared
after passing through the hemodialyzers or hemoffiters used in
this study. With progressive duration of HD or hemofiltration,
the total amount of irANP removed per minute from plasma
decreased in parallel with the plasma irANP concentrations;
however, the rate of plasma cleared across the hemodialyzer or
ultrafilter (on average approximately 25 or 50 mI/mm, respec-
tively) was constant throughout the treatment sessions, thus
pointing to a non-saturable process. Moreover, circulating
irANP was found to be at least in part dialyzable and ultrafilter-
able. Of the irANP cleared across hemodialyzers or ultrafilters,
about 14 or 30% appeared in the dialysate or ultrafiltrate,
respectively; the major fraction was therefore, rapidly metabo-
lized and/or bound to dialysis membrane, filters or plastic
components of the dialysis system. Compared with the total
plasma clearance of irANP in normal man, the local clearance
of irANP across hemodialyzers or hemofilters is trifling, and
consequently, probably contributes little to dialysis—induced
decreases in circulating irANP. Unchanged plasma levels after
isovolemic hemodialysis [23] support the latter conclusion.
The percentage responses of plasma irANP to changes in
posture were similar in our HD patients and normal subjects.
This indicates that, at least in the absence of congestive heart
failure or other clinical evidence of severe cardiac disease,
physiological stimuli of ANP-release are usually still perceived
normally in terminal renal failure. The distinct decrease in
irANP with the change from supine to upright posture is
thought to reflect the concomitant reduction in central circula-
tory volume [8] which, in turn, reduces atnal distension.
Regional plasma irANP concentrations in the HD patients
were on average 35% higher in the right atrial than in peripheral
venous plasma. In normal subjects, differences of 21% between
right ventricular and venous plasma [26] and in patients with
congestive heart failure 51% to 64% [20, 26] were noted. The
heart seems to release normally most, although not necessarily
all circulating ANP [6, 27] which disappears rapidly with
distinct arteriovenous concentration gradients in the renal,
peripheral and hepatic, but not pulmonary vasculature [6]. The
slight and statistically insignificant decrease in plasma irANP
from the right atrial, pulmonary arterial region to the peripheral
av-fistula in the HD patients probably reflects some venous
mixing of fistula blood rather than a transpulmonary elimination
of irANP. Partial mixing with venous blood may also account
for the only modest concentration gradient between the av-
fistulae and peripheral venous blood. On the other hand, an
altered rate of ANP metabolism in HD patients is not excluded.
Whether the ANP-system in end—stage kidney disease has
any pathophysiological relevance is presently unknown. Nev-
ertheless, the predominant ANP moiety in the circulation of
both HD patients and normal subjects, namely, ahANP has
potential biological activity. In fact, when synthetic ahANP is
infused into normal subjects, plasma irANP concentrations
comparable to those in some of our hemodialysis patients
produced a wide spectrum of effects which, apart from diuresis
and natriuresis, included an acute BP reduction, a fluid volume
shift from the blood space to the extravascular compartment, a
probably baroreflex—mediated sympathetic activation, inhibi-
tion of aldosterone synthesis, stimulation of plasma insulin, and
an acute increase in glomerular filtration rate [1, 6, 13—15].
Moreover, systematically infused ANP may exert similar ef-
fects in patients with mild to moderate chronic renal failure
(Suda S, Weidmann P, Saxenhofer H, Shaw S, Ferrier C;
unpublished data). Therefore, a possible contribution of the
ANP-system to homeostasis of BP, and at least in the pre-
oliguric phase, the regulation of the body sodium—fluid volume
state in the presence of impaired kidney function will deserve
particular consideration. In the meantime, the findings of the
present study demonstrate that in addition to the cardiac status,
age and posture should be considered when interpreting plasma
irANP levels as a possible index of sodium and fluid overload.
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